Trastuzumab deruxtecan, a HER2 antibody-drug conjugate also showed durable antitumor activity in patients with previously treated HER2-mutant non-small-cell lung cancer (NSCLC).The objective response occurred in 55% of the patients with a median duration of response 9.3 months, progression-free survival 8.2 months and overall survival 17.8 months [17]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.